Tempus was founded in 2010 by Eric Lefkofsky, who also founded Lightbank venture fund that invests in disruptive technology businesses. He is the author of “Accelerated Disruption: Understanding the True Speed of Innovation”. Tempus uses artificial intelligence and machine learning to collect, organize and analyze clinical data to help provide doctors with treatment for each individual patient. Tempus is led by Eric Lefkofsky and currently, its Lens platform works in the diagnosis and treatment of cancer but can also be used in the treatment of other conditions, such as diabetes and depression.
Tempus is working with biotechnology company A2 who’s developing innovative cell therapies for cancer patients. A press release at Pharmiweb.com in January, offered by Michael Yasiejko, chief commercial officer, said that Tempus would help A2 identify patients with unique biomarkers. Tempus offers comprehensive information in their immunotherapy platform (Youtube).
In May, Tempus released its Lens platform that allows access to one of the largest de-identified datasets. Scientists and researchers can use Lens to accelerate drug discovery and development. Lens allows pharmaceutical and biotechnology companies tools to gain insight in minutes, allowing real time data to guide care and treatment, and to find and develop medications that address patient populations. Lens Platform can be used to research prostate cancers in African American men. Tempus and the new Lens platform, Eric Lefkofsky points out, offers the largest libraries of clinical and molecular data in the world as well as an operating system that makes the data available to doctors and researchers in real time for data driven decision making. Tempus’s successes lead to better patient outcomes.